Ovarian Cancer Treatment Regimens

Share this content:

facebook
twitter
linkedin
google
Email
Print

Advertisement

Download: Ovarian Cancer Treatment Regimens

SEE BELOW THE CHART TO SEE GYNECOLOGIC CANCER DRUG MONOGRAPHS.

Continue Reading Below

OVARIAN CANCER TREATMENT REGIMENS

Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment.
Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an
experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive
care interventions should be administered accordingly. The ovarian cancer treatment regimens below may include both U.S. Food and Drug
Administration-approved and unapproved indications/regimens. These ovarian cancer treatment regimens are provided only to supplement the latest
treatment strategies.
These Cancer Treatment Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines®
are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any
NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or
treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use, or application and
disclaims any responsibility for their application or use in any way.

Primary Chemotherapy/Primary Adjuvant Therapy1abc

Note: All recommendations are Category 2A unless otherwise indicated.
Stage 1A or 1B (grade 2d, 3, or clear cell) & Stage 1C (grade 1–3)
REGIMEN DOSING
Paclitaxel + Carboplatin2 Day 1: Paclitaxel 175mg/m2 IV over 3 hours + carboplatin AUC 5-6
mg·min/mL IV over 1 hour.
Repeat every 3 weeks for 3 to 6 cycles.
Stage 2–4 (IV/IP regimen)e,f
Paclitaxel + Cisplatin Day 1: Paclitaxel 135mg/m2 continuous IV infusion over 3 or 24 hours
(Category 1)3 Day 2: Cisplatin 75–100mg/m2 IP
Day 8: Paclitaxel 60mg/m2 IP.
Repeat every 3 weeks for 6 cycles.
Stage 2–4 (IV regimens)g
Paclitaxel + Carboplatin Day 1: Paclitaxel 175mg/m2 IV over 3 hours + carboplatin AUC 5-6
(Category 1)4 mg·min/mL IV over 1 hour.
 Repeat every 3 weeks for 6 cycles.
Dose-dense Paclitaxel + Day 1: Paclitaxel 80mg/m2 IV over 1 hour + carboplatin AUC 5-6
Carboplatin (Category 1)5 mg·min/mL IV over 1 hour.
Day 8 and 15: Paclitaxel 80mg/m2 IV over 1 hour.
Repeat every 3 weeks for 6 cycles.
Paclitaxel + Carboplatin Day 1: Paclitaxel 60mg/m2 IV over 1 hour + carboplatin AUC 2
(Category 1)(for elderly mg·min/mL IV over 30 minutes.
patients and those with poor Repeat weekly for 18 weeks.
performance status)6
Docetaxel + Carboplatin Day 1: Docetaxel 60–75mg/m2 IV over 1 hour + carboplatin AUC 5-6
(Category 1)7 mg·min/mL IV over 1 hour.
Repeat every 3 weeks for 6 cycles.
Stage 2-4 (bevacizumab-containing IV regimens)h
Paclitaxel + Carboplatin + Day 1: Paclitaxel 175 mg/m2 IV over 3 hours + carboplatin AUC 5-6
Bevacizumab (Category mg·min/mL IV over 1 hour + bevacizumab 7.5 mg/kg IV over 30–90
2B)8–14 minutes.
Repeat every 3 weeks for 5 to 6 cycles.
Continue bevacizumab for up to 12 additional cycles.
OR
Day 1: Paclitaxel 175 mg/m2 IV over 3 hours + carboplatin AUC 6
mg·min/mL IV over 1 hour.
Repeat every 3 weeks for 6 cycles.
Starting Day 1 of cycle 2: Bevacizumab 15 mg/kg IV over 30–90
minutes every 3 weeks for up to 22 cycles.
Principals of Chemotherapy1
For patients with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer
• If they are eligible for chemotherapy, patients should be informed about the different options that
are available—that is, intravenously (IV) chemotherapy, a combination of intraperitoneal (IP) and IV
chemotherapy, or a clinical trial—so they can decide which is the most the appropriate option.
• Prior to the administration of the combined IP and IV regimen, patients must be apprised of the
increased toxicities with the combined regimen when compared to using IV chemotherapy alone
(increased myelosuppression, renal toxicities, abdominal pain, neuropathy, gastrointestinal toxicities,
metabolic toxicities, and hepatic toxicities).
• Patients considered for the IP cisplatin and IP/IV paclitaxel regimen should have normal renal
function prior to starting, a medically appropriate performance status based on the future toxicities of
the IP/IV regimen, and no prior evidence of medical problems that could significantly worsen during
chemotherapy (e.g., pre-existing neuropathy).
• Prior to receiving and after receiving each cycle of IP cisplatin, adequate amounts of IV fluids need
to be administered to prevent renal toxicity. After each cycle has been completed, patients need to
be monitored carefully for myelosuppression, dehydration, electrolyte loss, end-organ toxicities (such
as renal and hepatic damage), and all other toxicities. Patients often require IV fluids after
chemotherapy in the outpatient setting to prevent or help treat dehydration.
• Refer to the original references in the discussion section of the guideline for full toxicity data,
doses, schedule, and dose modifications.
For patients who have recurrent ovarian, fallopian tube, or primary peritoneal cancer
• Patients should be informed about the following:
» Availability of clinical trials, including the risks and benefits of various treatments, which will
depend on the number of prior lines of chemotherapy the patient has received, and
» The patient's performance status, end-organ status, and pre-existing toxicities from prior
regimens. If appropriate, palliative care should also be discussed as a possible treatment choice.
(See NCCN Guidelines for Palliative Care).
• Because of prior platinum exposure, myelosuppression occurs more frequently with any myelotoxic
agent given in the recurrent setting.
• With repeat use of either carboplatin and/or cisplatin, patients are at an increased risk of
developing a hypersensitivity reaction (also called an allergic reaction) that could be life-threatening.
Thus, patients should be counseled about the risk that a hypersensitivity reaction may occur,
educated about the signs and symptoms of hypersensitivity reactions, treated by medical staff who
know how to manage hypersensitivity reactions, and treated in a medical setting where appropriate
medical equipment is available in case of an allergic reaction. (See NCCN Guidelines for
Management of Drug Reactions [OV-C]).
• Before any chemotherapy drug is given in the recurrent setting, the clinician should be familiar with
the drug's metabolism (i.e., renal and hepatic) and should make certain that the patient is an
appropriate candidate for the drug (e.g., that the patient has adequate renal or hepatic function).
• Clinicians should be familiar with toxicity management and appropriate dose reduction.
• The schedule, toxicity, and potential benefits of any treatment should be thoroughly discussed with
the patient and caregivers. Patient education should also include a discussion of precautions and
measures to reduce the severity and duration of complications.
For elderly patients (>65 years) and/or those with comorbidities
• Elderly patients and those with comorbidities may be intolerant to the combination chemotherapy
regimens recommended in the NCCN Guidelines. Single-agent platinum agents may be appropriate
in selected patients
» Algorithms have been developed for predicting chemotherapy toxicity. (See the NCCN Guidelines
for Older Adult Oncology).
NOTE: Carboplatin dosing may be revised based on changes in serum creatinine methodology. See the FDA dosing statement
at: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm228974.htm.
a Patients receiving primary chemotherapy should be monitored as follows: 1) pelvic exams at least every 2–3 cycles, 2) interim
complete blood count with platelets as indicated, 3) chemistry profiles if indicated. 4) CA-125 levels or other tumor markers as
clinically indicated prior to each cycle of chemotherapy, 5) radiographic imaging if indicated.
b All primary chemotherapy/primary adjuvant therapy regimens (including the combined IV/IP chemotherapy) may be used for
epithelial ovarian, fallopian tube, and primary peritoneal cancers.
c Stage 1A or 1B (grade 2) can be observed or treated with chemotherapy.
d IP chemotherapy in <1 cm optimally debulked stage 2 and stage 3 patients (category 1 for stage 3).
e All women undergoing surgery for ovarian cancer should be counseled about the clinical benefit associated with combined IV
and IP chemotherapy administration prior to surgery.
f A 3-hour infusion of paclitaxel has not been proven to be equivalent to a 24-hour infusion, although it has been reported to be
more convenient , easier to tolerate, and less toxic.15
g IV regimens may be considered for neoadjuvant therapy.
h Bevacizumab-containing IV regimens based on the ICON-7 and GOG-218 trials. For additional information about this
controversial regimen, see the the NCCN Guidelines Insights: Ovarian Cancer.

References
1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology™. Ovarian Cancer including Fallopian
Tube Cancer and Primary Peritoneal Cancer. V.1.2016. Available at:
http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed February 2, 2017.
2. Ozols RF, Bundy BN, Greer BE, et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared
with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J
Clin Oncol. 2003;21:3194–3200.
3. Armstrong DK, Bundy B, Wenzel L, et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian
cancer. N Engl J Med. 2006;354:34–43.
4. Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal
doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011;
29(27):3628–3635.
5. Katsumata N, Yasuda M, Takahashi F, et al. Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in
combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial.
Lancet. 2009;374:1331–1338.
6. Pignata S, Scambia G, Katsaros D, et al; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs
Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European
Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators.
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a
randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014;15:396-405.
7. Vasey PA, Jayson GC, Gordon A, et al. Scottish Gynecological Cancer Trials Group. Phase III randomized trial of docetaxel
carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96:1682–
1691.
8. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N EngI J
Med. 2011;365:2473–2483.
9. Hall M, Gourley C, McNeish I, et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer.
2013;108:250–258.
10. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–
2496.
11. Morgan RJ Jr, Alvarez RD, Armstrong DK, et al. Ovarian cancer, version 3.2012. J Natl Compr Canc Netw 2012:10:1339–
1349.
12. Stark D, Nankivell M, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian
cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomized trial.
Lancet Oncol. 2013;14:236–243.
13. Monk BJ, Huang HQ, Burger RA, et al. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab
in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2013;128: 573–578.
14. Friedlander ML, Stockier MR, Butow P, et al. Clinical trials of palliative chemotherapy in platinum-resistant or -refractory
ovarian cancer: time to think differently? J Clin Oncol. 2013: 31:2362.
15. Barlin JN, Dao F, Bou Zgheib N, et al. Progression-free and overall survival of a modified outpatient regimen of primary
intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Gynecol Oncol. 2012;125(3):621–624.

(Revised 3/2017)
© 2017 Haymarket Media, Inc.

Gynecological Cancer Drug Monographs

Gynecologic Cancers

ALKERAN AVASTIN Bleomycin

Carboplatin Cisplatin COSMEGEN

Cyclophosphamide CYTOXAN INJECTION DEPO-PROVERA

DOXIL Doxorubicin HCl Doxorubicin HCl Solution

GEMZAR HEXALEN HYCAMTIN

LYNPARZA Megestrol acetate Methotrexate for injection

Methotrexate injection RUBRACA TAXOL

Thiotepa TREXALL Vinblastine for injection

Vinblastine injection ZEJULA

Data provided by the Monthly Prescribing Reference (MPR) Hematology/Oncology Edition.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.
Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions